PODD:NGS-Insulet Corporation (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 181.08

Change

-1.71 (-0.94)%

Market Cap

USD 2.13B

Volume

0.68M

Analyst Target

USD 241.41
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insulet Corp is a medical device company that develops, manufactures and sells OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 46.05B
ALGN Align Technology Inc

N/A

USD 19.27B
SWAV Shockwave Medical Inc

N/A

USD 12.57B
BRKR Bruker Corporation

N/A

USD 9.79B
MASI Masimo Corporation

N/A

USD 6.66B
TMDX TransMedics Group Inc

N/A

USD 4.52B
PRCT Procept Biorobotics Corp

N/A

USD 3.54B
AXNX Axonics Modulation Technologie..

N/A

USD 3.43B
TNDM Tandem Diabetes Care Inc

N/A

USD 3.20B
IRTC iRhythm Technologies Inc

N/A

USD 3.02B

ETFs Containing PODD

EDOC:AU BetaShares Digital Health.. 7.68 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 4.68 % 0.00 %

N/A

USD 2.39M
EDOC:LSE Global X Telemedicine & D.. 4.66 % 0.00 %

N/A

USD 4.72M
EDOG:LSE Global X Telemedicine & D.. 4.60 % 0.00 %

N/A

USD 0.15M
FDOC:LSE Fidelity Digital Health U.. 4.29 % 0.00 %

N/A

USD 2.85M
DDOC:XETRA Global X Telemedicine & D.. 4.18 % 0.00 %

N/A

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.18 % 0.00 %

N/A

USD 4.76M
EDOC:SW Global X Telemedicine & D.. 4.18 % 0.00 %

N/A

USD 4.69M
CYBG:LSE VanEck Bionic Engineering.. 3.91 % 0.00 %

N/A

USD 6.34M
FDHT 3.80 % 0.00 %

N/A

N/A
CIB0:XETRA VanEck Bionic Engineering.. 3.72 % 0.00 %

N/A

USD 6.31M
FDHT:XETRA Fidelity Digital Health U.. 3.61 % 0.00 %

N/A

USD 2.87M
GDOC Goldman Sachs ETF Trust 3.38 % 0.00 %

N/A

USD 0.03B
SLIM 0.00 % 0.50 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.05B
DTEC ALPS Disruptive Technolog.. 0.00 % 0.00 %

N/A

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.55% 52% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.55% 52% F 28% F
Trailing 12 Months  
Capital Gain -38.36% 48% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.36% 48% F 23% F
Trailing 5 Years  
Capital Gain 66.79% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.79% 84% B 75% C
Average Annual (5 Year Horizon)  
Capital Gain 11.28% 62% D 70% C-
Dividend Return 11.28% 62% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.39% 83% B 54% F
Risk Adjusted Return 32.78% 85% B 67% D+
Market Capitalization 2.13B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 54.39 31% 18%
Price/Book Ratio 16.75 14% 7%
Price / Cash Flow Ratio 86.98 2% 3%
Price/Free Cash Flow Ratio 40.13 7% 6%
Management Effectiveness  
Return on Equity 36.18% 100% 95%
Return on Invested Capital 11.34% 84% 80%
Return on Assets 6.74% 93% 90%
Debt to Equity Ratio 186.49% 15% 12%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.